Pharmaceuticals

MediLink Therapeutics closes US$70 million Series B financing

SUZHOU, China, March 14, 2022 /PRNewswire/ -- MediLink Therapeutics (Suzhou) Co., Ltd (MediLink) recently announced completion of aUS$70 million Series B financing. This round was led by LYFE Capital and Qiming Venture Partners, and co-invested by Legend Capital, Loyal Valley Capital and Highligh...

2022-03-14 20:50 2957

SOPHiA GENETICS and REALM IDx Sign Letter of Intent to Collaborate in Accelerating Cancer Research

The intended collaboration aims to help improve patient care by enhancing next-generation sequencing research for cancer care and expanding data sources for precision medicine. BOSTON, ALISO VIEJO, Calif. and LAUSANNE, Switzerland, March 14, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH) an...

2022-03-14 20:28 3084

NuclixBio Announces a Collaborative Research Agreement with PharmAbcine

SEOUL, South Korea, March 14, 2022 /PRNewswire/ -- NuclixBio Inc., a South Korean biotech company that focuses on research and development of mRNA therapeutics, announced today that it has signed a Collaborative Research Agreement with PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech...

2022-03-14 20:00 2763

111, Inc. Becomes First Online Retail Platform for BGI's SARS-CoV-2 Virus Antigen Detection Kits

SHANGHAI, March 14, 2022 /PRNewswire/ -- On March 14, 2022, 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company signed a strategic cooperation agreement with Shenzhen BGI Co., Ltd. (SZ: 300676) under which BGI will supply its SARS-CoV-2 Virus Ant...

2022-03-14 19:35 2460

Clarivate Deals Report Highlights Emerging Trends in Biopharma Deal-Making

RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology related deals dominate the landscape Biotech companies in U.S. awarded largest sums of capital, followed by Mainland China and UK LONDON, March 14, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in provid...

2022-03-14 16:00 2661

Hexvix® Has Obtained CDE Approval for the Inclusion In the Clinical Real-world Evidence Pilot Study

SHANGHAI, March 14, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global innovative biopharma company specializing in discovering and developing innovative drugs for the treatment of genitourinary tumors and other major diseases, announced that the Hainan Provincial Medical Products...

2022-03-14 14:25 2112

Impact Therapeutics Announces Completion of Series D1 Financing

SHANGHAI, March 14, 2022 /PRNewswire/ -- IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, announced the successful completion of its Series D1 financing. Institutional investors that par...

2022-03-14 12:43 2532

CStone announces the NMPA approval of GAVRETO (pralsetinib) for the treatment of Advanced or Metastatic RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer

* GAVRETO is the first and only selective rearranged during transfection (RET) inhibitor approved inChina for the treatment of RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer (TC) * The labeled indications of GAVRETO have been expanded after it was approved by...

2022-03-14 08:05 4563

Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Commercialize NEFECON in South Korea

SHANGHAI, March 14, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs inAsia Pacific markets, announced today that...

2022-03-14 08:00 4986

Ascletis Announces Further Expansion of Ritonavir Oral Tablet Production Capacity to 530 Million Tablets Per Year

HANGZHOU, China and SHAOXING, China, March 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (Ascletis, HKEX: 1672) today announces that it has further expanded its ritonavir oral tablet production capacity to approximately 530 million tablets per year, to meet the potential escalation in the domesti...

2022-03-13 18:30 4725

NMPA Clears IND for First T-Cell Receptor (TCR) T Cell Therapy to Treat Hepatitis B virus (HBV) associated hepatocellular carcinoma (HCC)

SINGAPORE, March 11, 2022 /PRNewswire/ -- Singapore-based SCG Cell Therapy Pte Ltd ("SCG"), a leading biotechnology company, today announced that the China National Medical Products Administration (NMPA) has cleared its Investigational New Drug (IND) application for SCG101, the company's first T-...

2022-03-11 21:07 5551

Gan & Lee Pharmaceuticals Begins First-In-Human Trial in U.S. for Investigational Drug, GZR18

BEIJING and BRIDGEWATER, N.J., March 11, 2022 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is pleased to announce the first subject has been dosed in our Phase I, double-blinded, randomized, placebo-controlled, sequential, sing...

2022-03-11 03:35 4623

Novavax Announces Launch of Global Vaccine Education Programs

-  'We Do Vaccines' and 'Know Our Vax' are new educational efforts that provide information regarding vaccines -  Programs explain Novavax' commitment to vaccine development and innovation GAITHERSBURG, Md., March 10, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company de...

2022-03-10 22:00 5029

THE WORLD'S FIRST ACADEMIC PAPER ON THE POTENTIAL USE OF VIRTUAL REALITY IN MODULATING PSYCHEDELIC-ASSISTED PSYCHOTHERAPY PUBLISHED BY THE CO-FOUNDERS OF ENOSIS THERAPEUTICS

The Peer-Reviewed Article Published In Volume 13 March 2022 Issue Of Frontiers In Psychology Journal Is A Landmark Examination Of Virtual Reality Therapy Combined With Psychedelic Therapy.  MELBOURNE, Australia, March 10, 2022 /PRNewswire/ -- The world's first scientific paper offering a careful...

2022-03-10 21:00 2267

Everest Medicines Announces that Licensing Partner Venatorx Pharmaceuticals Reports Positive Results from Pivotal Phase 3 Cefepime-Taniborbactam Trial

SHANGHAI, March 10, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Venatorx Pharmaceuticals, reported positive results from its pivotal Phase 3 study, CERTAIN-1 (Cefepime Rescue with Taniborbactam in cUTI), evaluating cefepime-taniborbactam, an in...

2022-03-10 19:05 4408

Transcenta Presented Safety / Tolerability and Preliminary Anti-tumor Activity Data in Gastric and Pancreatic Cancers of TST001 Monotherapy from China Phase I Clinical Trial at the 2022 International Gastric Cancer Congress

SUZHOU, China, March 10, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that Transcenta has ...

2022-03-10 08:30 4277

Bridge Biotherapeutics to Present Preclinical Data of BBT-207 at the AACR 2022 Annual Meeting

* The abstract of BBT-207 pre-clinical studies is now available at the AACR website * Preclinical data suggests that BBT-207 may have the potential to be positioned as a frontline treatment with the anti-tumor effects in EGFR mutant NSCLC SEONGNAM, South Korea, March 9, 2022 /PRNewswire/ -- B...

2022-03-10 07:00 2311

Insilico Medicine enters research collaboration with the University of Zurich to apply Insilico's generative Artificial Intelligence platform for the discovery of potential therapeutics for Cystinosis

- Cystinosis is a rare genetic disease affecting 1 in 100,000-200,000 live births and poses a lifelong risk to those affected. Cystinosis slowly destroys the body's organs including the kidneys, eyes, thyroid, muscles, liver, pancreas, gonads, and brain. - There are currently no curative treatme...

2022-03-10 00:57 3081

I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting

SHANGHAI and GAITHERSBURG, Md., March 9, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that two poster presentations featuring translational r...

2022-03-09 21:00 2287

Kusum Healthcare recognized as one of Best Places to Work in Philippines for 2022

MANILA, Philippines, March 9, 2022 /PRNewswire/ -- Kusum Healthcare, a leading tech-driven pharmaceutical group, has been recently awarded the Best Place to Work certification inPhilippines for 2022. During the company assessment, 97% of employees recommended the organization illustrating the com...

2022-03-09 20:22 2432
1 ... 292293294295296297298 ... 343